Trials of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, are documenting its direct kidney effects and broad benefits for diabetic kidney disease.

Chronic kidney disease affects 1 in 7 U.S. adults, underscoring the importance of early detection and management. This ...

An important finding from the study concerns a gene called APOL1. Two variants of the APOL1 gene, known as G1 and G2, ...

The 9th Annual Patient Symposium offers educational seminars on dialysis, nutrition, mental health and treatment options, ...

This article is part of “Innovations In: Kidney Disease,” an editorially independent special report that was produced with financial support from Vertex. More than one in seven people in the U.S. have ...

Recently analyzed evidence points to a connection between oral health and kidney health, according to work led by University ...

Researchers from the Faculty of Medicine at Chulalongkorn University have identified a native probiotic strain, Lactobacillus ...

Equations underestimate the slope of renal decline over time In chronic kidney disease care, the central clinical question is ...

A recent case study found a possible new trigger for a dangerous, and sometimes fatal, virus that could be laying dormant in ...

And it only takes a few minutes.

A national clinical trial is underway to test a device that could help patients with chronic kidney disease during the ...